Posted by Michael Wonder on 25 Feb 2021
AbbVie’s Skyrizi for the treatment of moderate to severe plaque psoriasis now publicly reimbursed across Canada
24 February 2021 - Prince Edward Island lists Skyrizi on its Pharmacare Formulary effective 22 February 2021.
AbbVie announced today that Skyrizi (risankizumab) is now listed as a special authorisation drug on the formulary of Prince Edward Island for the treatment of moderate to severe plaque psoriasis.
With the addition of the PEI formulary listing, Skyrizi is now listed for public payer coverage in all Canadian jurisdictions.
